Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.48 |
| ▸ | KLK7 | P49862 | 2/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21891736 | 0.93 | SIRT1 (0.54) | SIRT1SIRT2 | |
| SCHEMBL21891738 | 0.90 | SIRT1 (0.50) | SIRT1SIRT2 | |
| SCHEMBL21891789 | 0.89 | SIRT1 (0.51) | SIRT1SIRT2 | |
| SCHEMBL23766786 | 0.88 | SIRT1 (0.50) | SIRT1SIRT2KLK7KLK5CTSK | |
| SCHEMBL26862002 | 0.87 | SIRT1 (0.56) | SIRT1SIRT2KLK7KLK5MAPT | |
| SCHEMBL26862910 | 0.85 | SIRT1 (0.49) | SIRT1SIRT2KLK7KLK5MAPT | |
| SCHEMBL26862955 | 0.82 | NPSR1 (0.50) | SIRT1SIRT2KLK7KLK5MAPT | |
| SCHEMBL12890798 | 0.81 | MEN1 (0.52) | SIRT1KLK7KLK5CTSKMAPT | |
| SCHEMBL26863095 | 0.81 | SIRT1 (0.48) | SIRT1SIRT2KLK7KLK5MAPT | |
| SCHEMBL21892106 | 0.80 | SIRT1 (0.43) | SIRT1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827586-B2 | Method for producing amino acid aminoalkyl ester or inorganic acid salt thereof | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-11-28 | — | — | US | disclosed |
| US-20210253517-A1 | METHOD FOR PRODUCING AMINO ACID AMINOALKYL ESTER OR INORGANIC ACID SALT THEREOF | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253517-A1 | METHOD FOR PRODUCING AMINO ACID AMINOALKYL ESTER OR INORGANIC ACID SALT THEREOF | SLC6A15, SLC6A19, ALAD | SIRT1 4832/4885SIRT2 4322/4885KLK7 1349/4885 |
| US-11827586-B2 | Method for producing amino acid aminoalkyl ester or inorganic acid salt thereof | SLC6A15, SLC6A19, ALAD | SIRT1 4832/4885SIRT2 4322/4885KLK7 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.